As Major Insulin Producers Shift Focus, rBIO Steps Up to Address Potential Shortages
Recent price cuts by major insulin manufacturers may appear to address affordability challenges, but they primarily target older insulin drugs nearing patent expiration. This tactic, coupled with the ...
Le Lézard5d
As Major Insulin Producers Shift Focus, rBIO Steps Up to Address Potential Shortages
rBIO's biosimilar insulin, R-biolin, achieves bioequivalence to Novo Nordisk Novolin® R in animal studies; company prepares for 50x scale-up and readies for in-human studies HOUSTON, Feb. 4 ...
Insight News6d
Attorney General Keith Ellison secures $35 Novo Nordisk insulin for Minnesotans
For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.
Medscape2d
Room-temperature Storage of Medications Labeled for Refrigeration
human insulin isophane suspension (rDNA origin) Novolin N vial (Novo Nordisk) 30 days Prescribing information Regular human insulin injection (rDNA origin) Novolin R vial (Novo Nordisk ...
verywellhealth4d
A Complete Guide to Type 1 Diabetes Medications
Type 1 diabetes is a chronic condition caused by an autoimmune reaction, in which your body attacks the cells in your pancreas that make the hormone insulin. Treatment typically involves daily insulin ...